SCHEMBL2702373

SCHEMBL2702373

O=C(CCc1ccc(F)cc1)N1CCC(Cc2cccc(Cl)c2)(C(=O)O)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.50
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
EPHX2 P34913 1/20 0.48
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.45
NPC1 O15118 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
GPR183 P32249 1/20 0.43
USP7 Q93009 1/20 0.43
CACNA1F O60840 1/20 0.43
HTR1A P08908 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
DRD4 P21917 1/20 0.43
DRD5 P21918 1/20 0.43
HRH2 P25021 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
ADRA1A P35348 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2702117 0.88 GFER (0.60) GFERMEN1KMT2AEPHX2ALDH1A1
SCHEMBL2472171 0.84 ALDH1A1 (0.46) GFERMEN1KMT2AEPHX2ALDH1A1
SCHEMBL2704006 0.83 MEN1 (0.60) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL2702754 0.81 NPC1 (0.63) GFERMEN1KMT2AEPHX2ALDH1A1
SCHEMBL2701536 0.80 GFER (0.53) GFERMEN1KMT2AEPHX2MAPT
SCHEMBL2701727 0.79 ALDH1A1 (0.59) GFERMEN1KMT2AALDH1A1MAPT
SCHEMBL2469451 0.78 PLAAT3 (0.49) GFERMEN1KMT2AEPHX2ALDH1A1
SCHEMBL12194797 0.78 GFER (0.56) GFERMEN1KMT2AEPHX2ALDH1A1
SCHEMBL2472142 0.77 GFER (0.55) GFERMEN1KMT2AEPHX2NPC1
SCHEMBL2469409 0.77 GFER (0.55) GFERMEN1KMT2AEPHX2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 GFER 1562/4885MEN1 3501/4885KMT2A 957/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 GFER 1562/4885MEN1 3501/4885KMT2A 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.